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Abstract

Metabolic syndrome is a cluster of five factors (elevated systolic blood pressure,
elevated blood glucose, elevated triglycerides, large waist circumference, and decreased
HDL) that are related to a greater chance of heart disease, stroke, and diabetes. There is
evidence that metabolic syndrome is correlated with depression, but the directionality and
mechanism is unclear. There is also dispute in the literature as to whether there is a
correlation with anxiety and metabolic syndrome. In this study, levels of depression and
anxiety determined from questionnaires and interviews (Adult Self Report, Child
Behavior Checklist, Kiddie Schedule for Affective Disorders and Schizophrenia-Present
and Lifetime, and the Composite International Diagnostic Interview) were compared with
the five factors of metabolic syndrome in 100 three-person families. In children and
adolescents, elevated triglycerides were predictive of elevated depressive behavior above
the age of 12.68 (p <.05), with the significance increasing with age. In adults, anxious
behavior was predictive of overall metabolic risk, HDL, and waist circumference when
controlling for age, sex, and SES (p <.01, p <.05, and p < .05 respectively). Additionally,
a lower SES, older age, greater anxious behavior, and being male were all predictive of
greater overall metabolic risk. Results implicate an age-moderated difference in how
metabolic factors affect depression in children, possibly having a mechanism coinciding
or affected by puberty. In adults, the directionality seems to reverse, with the anxious
behavior having an effect on the metabolic syndrome factor, possibly related to stress and
inflammation. Further research is needed to study these mechanisms and elucidate the
connections between the disorders.
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Introduction

Metabolic Syndrome
Metabolic syndrome is one of the most formidable challenges in contemporary
public health (Kaur, 2014). The disease, defined as a group of risk factors, including
visceral obesity, unhealthy blood fat content, high blood pressure, and high blood sugar,
is associated with three of the six leading causes of death worldwide: cardiovascular
disease, stroke, and diabetes (WHO World Health Report, 2017). Individuals with
metabolic syndrome are five times more likely to develop type 2 diabetes, two times
more likely to develop cardiovascular disease within 5 to 10 years of being diagnosed
with metabolic syndrome, and 2 to 4 times more likely to suffer a stroke (Alberti et al.,
2009; Alberti, Zimmet, Shaw, & Group, 2005). In the United States, between 2003 to
2012, the overall prevalence of the syndrome was 33%, with significantly higher rates
among females (35.6%) than males (30.3%; (Aguilar, Bhuket, Torres, Liu, & Wong,
2015). Additionally, age is a risk factor for metabolic syndrome, with a prevalence of
50% in adults over the age of 60 (Aguilar et al., 2015).
More specifically, the National Institutes of Health National Heart, Lung, and
Blood Institute (2016) defines metabolic syndrome as the presence of a cluster of at least
three of the following factors in an adult over age 21:
1.) Large waist circumference (>40 inches for men; >35 inches for women)
2.) High triglycerides (>150 mg/dL)
3.) Low high-density lipoprotein (HDL), commonly referred to as “good
cholesterol” (<40 mg/dL for men; <50 mg/dL for women)
4.) High fasting glucose (>100 mg/dL)
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5.) Elevated blood pressure (>130/85 mm HG)
A BMI classified as “obese” (i.e. over 30 kg/m2), though not an explicit component of the
NIH’s definition of metabolic syndrome, is also considered a risk factor for metabolic
problems (Kaur, 2014). Each of these factors is related to metabolic risk, for related, but
slightly different, reasons.
Larger waist circumference is indicative of increased stores of adipose tissue in
the abdomen, often resulting from low physical activity and the consumption of caloriedense foods (Kaur, 2014). Adipose tissue stores triglycerides, and contains a variety of
cell types, such as adipocytes and immune cells (Halberg, Wernstedt-Asterholm, &
Scherer, 2008; Schmidt et al., 2015). An adipocyte is an endocrine cell, known to secrete
substances including cortisol, a stress hormone, and pro-inflammatory factors, such as
cytokines (Lau, Dhillon, Yan, Szmitko, & Verma, 2005). When these substances are
secreted, they can cause an adverse metabolic effect, as the adipose tissue’s local
inflammation proliferates into systemic chronic low-grade inflammation (Trayhurn &
Wood, 2004). Inflammation often precedes the development of diabetes, and is predictive
of future weight gain (Engstrom et al., 2003; Rodriguez-Hernandez, Simental-Mendia,
Rodriguez-Ramirez, & Reyes-Romero, 2013; Thorand et al., 2003).
HDL (“good cholesterol”) functions by carrying low-density lipoproteins (“bad
cholesterol”) to the liver, which then removes them. High levels of low-density
lipoproteins are related to artery hardening, which results in impeded blood flow.
Therefore, low levels of low-density lipoprotein have negative metabolic effects, whereas
high levels HDL promote good metabolic health (Mayo Clinic, 2015; American Heart
Association, 2017).
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Triglycerides are a measure of the amount of lipids in the blood. They store
unused calories and provide the body with energy when there is low blood glucose
between meals. High levels of triglycerides contribute to artery wall thickening and
hardening, known as atherosclerosis, and are linked to the increased risks of stroke and
cardiovascular disease (American Heart Association, 2017; Mayo Clinic, 2015).
Fasting glucose levels are a measure of the amount of glucose in the blood after
fasting for at least eight hours. Glucose, a simple sugar, is derived from food and is used
to generate energy for the body’s cells. After eating, glucose enters the bloodstream via
the intestines, and results in a blood sugar “spike”. After fasting, if levels are high it
indicates that the body is not utilizing insulin properly for transporting glucose into cells.
This suggests the presence of diabetes or a prediabetic state, and over time can also lead
to problems such as heart attacks and strokes (American Diabetes Association, 2017;
Joslin Diabetes Center, 2017).
Systolic blood pressure refers to the pressure in the arteries during cardiac muscle
contraction (ventricular systole). A high systolic blood pressure may be caused by an
unhealthy lifestyle, medications, and stress-induced vasoconstriction (artery narrowing)
among other reasons. High systolic blood pressure is a known risk factor of
cardiovascular disease and stroke (Reece, Wasserman, Campbell, & Yunagisawa, 2011).
Finally, a high BMI is indicative of large quantities of visceral body fat, and can
be regarded as a predictor of metabolic syndrome independent of waist circumference. In
clinical practice and research, BMI can serve as a simple indicator of body fat and
metabolic risk (Janssen, Heymsfield, Allison, Kotler, & Ross, 2002).
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Psychological Connections
In addition to negative physiological outcomes, several studies have indicated a
link between metabolic syndrome and psychiatric disorders. In particular, these
associations have been well studied in relation to schizophrenia and bipolar disorder.
Metabolic syndrome has a comorbidity rate as high as 60% among individuals with
schizophrenia (Meyer, Koro, & L'Italien, 2005). The literature suggests many possible
reasons, including side effects of medication usage, lifestyle, and a common pathogenic
pathway involving sphingolipids. Amongst their other functions sphingolipids are
involved in inflammation. Inflammation as a result of obesity can lead to glucose
intolerance. It can also reduce white matter and myelination in the brain, leading to
abnormal brain circuitry and psychotic symptoms resulting in schizophrenia (Castillo et
al., 2016).
Bipolar disorder is also associated with a higher risk of metabolic syndrome than
in the general population (McIntyre et al., 2010). Even when controlling for medication
and health habits, individuals with bipolar disorder have been shown to be at greater
cardiovascular risk. This has lead researchers to believe that dysregulated inflammatory
pathways may underlie these disorders (Leboyer et al., 2012) This pathway is possibly
mediated by cytokines, which are part of the immune system’s inflammatory response,
and are elevated during episodes of mania and depression (Leboyer et al., 2012). In a
study examining metabolic syndrome, schizophrenia, and bipolar disorder, metabolic
syndrome was more likely to occur in individuals with schizophrenia and bipolar disorder
than controls, even when controlling for exercise, diet, and smoking (Bly et al., 2014).
These findings support the multi-systemic nature of bipolar disorder, as it is indicates that
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its effects are related to more than one body system. In response to this research on
bipolar disorder and schizophrenia and multi-systemic theories, increased emphasis has
been placed on conceptualizing and studying psychiatric disorders as disorders of not
only the mind, but also the body (Leboyer et al, 2012). However, to date, the evidence
supporting this theory in relation to other psychiatric disorders, namely anxiety and
depression, remains mixed.
With regard to anxiety disorders, several studies have identified metabolic
associations. For example, a study looking at Vietnam war veterans found that a
diagnosis of generalized anxiety disorder was positively associated with metabolic
syndrome, whereas depression was not (Carroll et al., 2009). Similarly, another study by
Luppino and colleagues (2011) found a strong association between most metabolic
syndrome components and anxiety-specific affects, but not depression-specific affects.
By contrast, however, other recent studies have found that the prevalence of
metabolic syndrome was greater only in individuals with depression, but not anxiety
(Butnoriene, Bunevicius, Norkus, & Bunevicius, 2014). Another study found that as
levels of depression increased, the number of components of metabolic syndrome
exhibited also increased, even when controlling for obesity, smoking status,
socioeconomic status, age, lifestyle, and comorbidity with anxiety. This relationship was
not observed with anxiety symptoms (Skilton, Moulin, Terra, & Bonnet, 2007).
Other studies have found no association between depression or anxiety and
metabolic problems. For example, a study in Finland found that after sex, alcohol
consumption, smoking, marital status, education level, and physical activity were
controlled for, metabolic syndrome was not associated with anxiety or depression in
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young adults (Herva et al., 2006). Affirming these findings, a large longitudinal study
conducted in Norway found no association between anxiety and depression and future
metabolic syndrome (Hildrum, Mykletun, Midthjell, Ismail, & Dahl, 2009).
In summary, the literature on the relations between anxiety, depression and
metabolic problems remains unclear. To date, the majority of the research has focused on
depressive disorders and additional research is needed to understand the metabolic effects
of both anxiety alone and comorbid with depression.

Significance
More research is needed to investigate the interactions between metabolic
syndrome, anxiety disorders, and depressive disorders in order to address the
inconsistencies in the literature and determine if a common mechanism may connect
these disorders. This is particularly important to understand, as anxiety and depressive
disorders are very common. In the United States, there is an 18.1% prevalence rate of
past year anxiety disorders in adults (Kessler, Berglund, et al., 2005; Kessler, Chiu,
Demler, Merikangas, & Walters, 2005) and a 6.7%, prevalence rate of past year major
depressive episodes (National Survey on Drug Use and Health, 2016). Given this high
prevalence, it is important to research to have scientific consensus regarding whether
these disorders may be a risk factor for metabolic syndrome, or its components. This will
enable further research into specific mechanisms and associations, which can help
improve treatments, diagnoses, and screening. As stated by Chapman and colleagues,
“Research examining the association between depressive disorders and chronic disease
suggests that timely diagnosis and treatment of psychiatric disorders could greatly affect
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the impact of chronic disease. The presence of mental illness may be an important
contributor to the etiology of chronic disease. Thus, the promotion of mental health
would likely result in reducing a considerable proportion of the burden of chronic
disease.” (Chapman, Perry, & Strine, 2005). There is sufficient evidence to believe that
this rationale could be extended to anxiety and depressive disorders.
Furthermore, understanding the relations between these disorders may also help
control the cost of healthcare. In the United States, 75% of healthcare finances are spent
on chronic diseases. The Centers for Disease Control and Prevention (CDC), reported
that $313.8 billion dollars were spent on cardiovascular disease and stroke in 2009, as
well as $116 billion spent on diabetes in 2007 (2009). In contrast with the costs of
depression and anxiety, which average $210.5 billion and $42 billion per year,
respectively. Therefore, if a connection between anxiety and depression can be
empirically established, it is possible that early identification and treatment of depression
and anxiety could prevent the development of more costly and chronic metabolic
conditions. This has the potential to reduce healthcare cost by billions of dollars
(Greenberg, Fournier, Sisitsky, Pike, & Kessler, 2015; Greenberg et al., 1999).
Finally, a novel element of the current study is that it examines metabolic
symptoms in relation to anxiety and depression in both adults and children. While
previous studies have looked at obesity and anxiety and depression in children, to our
knowledge, the specific associations between elevated metabolic syndrome components
and anxiety and depression symptoms have not been examined (Anderson, Cohen,
Naumova, Jacques, & Must, 2007; Weiss et al., 2004). It is important to understand the
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development of disorders from an early age, as it can lead to earlier screening,
identification and intervention.

Hypotheses
Based on the existing literature, it was hypothesized that all of the individual
components of metabolic syndrome would be positively correlated with the presence of
depressive symptoms. As the literature indicates that depression is correlated with
metabolic syndrome more often than anxiety, it was also hypothesized that the presence
of anxiety symptoms would not be significantly correlated with metabolic syndrome
components. Finally, it was hypothesized that the relations between anxiety, depression,
and metabolic syndrome components would be consistent for adults and children. As
there is a lack of literature looking at children, adults, and metabolic syndrome, there was
no reason to hypothesize that there would be a difference between children and adults.

Methods
Participants
This study constitutes a secondary analysis of data obtained from a family study
on emotion regulation conducted in the University of Vermont Child Emotion Regulation
Laboratory under the direction of Dr. Robert Althoff (Committee on Human Research in
Medical Sciences #13-275). Eighty-three family units, each consisting of one proband
accompanied by either two biological parents, or one biological parent and one full
biological sibling, were recruited from both a pediatric psychiatry clinic and the
community. In addition to the presence of biological family members, recruitment criteria
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for the proband included either the presence of emotion dysregulation problems, or the
ability to be a clean control or psychiatric control. Subjects were chosen for this
secondary analysis based on the availability of questionnaire, blood draw, and
morphometric data.
As seen in Table 1, the mean socioeconomic status of families in this sample was
65.43 on the Hollingshead scale, which corresponds to middle class status. There were
140 total children, of which 65.7% of the children in the sample were male (0=female,
1=male) and the mean age was 11.36 years. All children were between the ages of 7 to
17. Among the children there were 56 sibling pairs in the sample. There were 117 adults,
with 30.8% of the sample being male (0=female, 1=male), and a mean age of 43.51
years.
The original purpose of this study was to examine the relations between emotion
dysregulation and metabolic problems. Therefore, the mean level of emotional-behavioral
problems was higher in the children than in the general population. Based on the Child
Behavior Checklist, the average score for total emotional-behavioral problems was at the
69th percentile. More specifically, the mean level of withdrawn and anxious symptoms
were at the 71st and 69th percentile, respectively, for children in this sample. Adults had a
slightly above average total problems score in the 54th percentile. They had an average
withdrawn score in the 63rd percentile and an average anxious-depressed score in the 67th
percentile. Written informed consent and assent was obtained from all subjects prior to
participation in the study. No exclusions were made based on sex, race, or ethnic
background.
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Measures
Child Behavior Checklist
The Child Behavior Checklist (CBCL) is a parent-report questionnaire that
assesses children’s emotional, behavioral and social problems during the past 6 months.
The questionnaire consists of 113 problem items that are rated on a 3-point scale of 0
(“Not true”), 1 (“Somewhat or Sometimes True”), or 2 (“Very True or Often True”),
which have been factor-analytically reduced to 8 syndrome scales that are consistent
across age, informant, and culture (Achenbach & Rescorla, 2001). The psychometrics of
these scales have been well characterized with test-retest reliabilities ranging from 0.74 to
0.95 and Cronbach alphas ranging from 0.79 to 0.97. For the purposes of this study, raw
scores on the Anxious-Depressed and Withdrawn-Depressed syndrome scales were used.
Because most parents in the sample were mothers, whenever available, the maternal
report was used for consistency.

Adult Self Report
The Adult Self Report (ASR) is a self-report questionnaire analogous to the
CBCL, that assesses emotional, behavioral, social, and substance use problems during the
past 6 months. Similar to the CBCL, adults reported on problem behaviors on a 3-point
scale for 123 problem items. These items have been factor-analytically reduced to 8
syndrome scales that are consistent across age, informant, and culture. The psychometrics
for these scales have been well characterized with rest-retest reliabilities ranging from
0.87 to 0.91 and Cronbach alphas ranging from 0.83 to 0.88. For this study, raw scores on
the Anxious-Depressed and Withdrawn-Depressed syndrome scales were used.
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Blood Draw and Morphometric Data
In accordance with the recommendations of the National Cholesterol Education
Program (NCEP), height, weight, and waist circumference (measured halfway between
the iliac crest and the lowest rib), blood pressure and resting heart rate data were
collected from all participants. Body Mass Index (BMI) was calculated from height and
weight.
Additionally, a blood sample was taken to obtain plasma glucose, triglycerides,
HDL, and insulin measurements. Participants were required to fast for at least eight hours
prior to the blood draw. After the blood draw, participants were given $5.00 vouchers to
purchase breakfast at the University of Vermont Medical Center Dining Facilities. If
adults were treated for hypertension, diabetes, or hyperlipidemia, the type and dosage of
medication was recorded. In order to standardize the scales for each morphometric and
metabolic factor (waist circumference, systolic blood pressure, fasting glucose, highdensity lipoproteins, and triglycerides), the factors were first z-transformed. High-density
lipoprotein scores were transformed so that higher scores would reflect lower levels, and
therefore, a greater metabolic risk. Then, the factors that comprise metabolic syndrome
were averaged to compute overall metabolic risk. Due to a smaller sample size for data
from the blood draw (ntotal = 178, nkids = 89, nadults = 89) the Z scores were not summed in
order to avoid underestimating metabolic risk for people with missing data. The
metabolic risk score was calculated separately for the full sample, for adults only, and for
children only.
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Statistics
Pearson’s correlation and multiple hierarchical regression analyses were
conducted using IBM SPSS Statistics version 24. Then, the PROCESS macro 2.16 was
used to conduct follow-up simple slope analyses to examine the nature of interaction
effects (Hayes, 2016).

Results
Tables 1 and 2 present the descriptive statistics and Pearson’s correlations
between all variables of interest. Using the results of the Pearson’s correlations, analyses
were initially run on the full sample, and then broken down into adults and children.

Full Sample
A hierarchical multiple regression analysis was conducted predicting the overall
metabolic risk for the full sample. At step one, SES, sex, and age were entered as
covariates. At step two, anxious-depressed symptoms were added to the model. The
overall model was significant and accounted for 35% of the variability in the overall
metabolic risk score (R2 .35, F [4, 192] = 25.81, p <.001) with the addition of anxiousdepressed symptoms uniquely contributing 1.4% of the variance (ΔR2 = .01, ΔF [1, 192]
= 4.20, p <.05). More specifically, age (b = .02, t[192] = 8.32, p <.001), and anxiousdepressed symptoms (b = .02, t[192] = 2.05, p < .05) had significant positive effects on
overall metabolic risk. SES (b = -.01, t[192] = -3.38, p = .001) had a significant negative
effect on overall metabolic risk, and sex (b = .52, t[192] = 5.61, p <.001) had an effect
such that males had a higher metabolic risk than females. The same procedure was
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repeated using withdrawn-depressed symptoms at step two to predict overall metabolic
risk. The model was significant and predicted 33% of the variance in withdrawndepressed symptoms (R2 =.33, F [4, 192] = 25.20, p <.001). However, the addition of
withdrawn-depressed symptoms at step two was not significant.

Adults
We repeated the hierarchical multiple regression analysis to investigate anxiousdepressed symptoms on overall metabolic risk in adults only. Sex, age, and SES were
used in step one of the analysis to predict overall metabolic risk in adults. In step two,
anxious-depressed symptoms were added. The overall model was significant, accounting
for 38% of the variability in metabolic risk (R2 = .38, F [4, 92] = 13.92, p <.001). The
addition of anxious-depressed symptoms uniquely contributed 4.8% of the variance (ΔR2
=.05, ΔF [1, 92] = 7.07, p <.01). Age (b = .03, t[92] = 2.84, p < .01) and anxiousdepressed symptoms (b = .03, t[92] = 2.66, p < .01) had positive significant effects on
metabolic risk, whereas SES (b = -.007, t[92] = -2.36, p < .05) had a significant negative
effect on metabolic risk. Sex (b = .71, t[92] = 5.39, p <.001) also had an effect such that
adult males had a higher metabolic risk than adult females.
To further investigate the relations between anxious-depressed symptoms and
metabolic problems, we conducted hierarchical multiple regressions predicting each of
the individual metabolic components that were significantly correlated with anxiousdepressed symptoms in Table 2. In the first regression with HDL as the dependent
variable, age, sex, and SES were entered at step one. In step two, anxious-depressed
symptoms were added. The overall model was significant, accounting for 21% of the
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variance in HDL (R2 = .21, F [4, 74] = 4.97, p <.001), with anxious-depressed symptoms
uniquely accounting for 5.4% of the variance (ΔR2 =.05, ΔF [4, 74] = 5.07, p <.05).
Anxious-depressed symptoms (b = .04, t[74] = 2.25, p <.05) had a significant positive
effect on HDL. Sex (b = .82 t[74] = 3.72, p <.001) also had an effect such that being male
was associated with having lower levels of HDL.
This model was repeated predicting waist circumference. The overall model was
significant, predicting 32% of the variance in waist circumference (R2 =.32, F [4, 91] =
10.79, p <.001) with anxious-depressed symptoms uniquely predicting 4.4% of the
variance in waist circumference (ΔR2 =.04, ΔF [1, 91] = 5.86, p <.05). SES (b = -.01
t[91] = -2.90, p < .01) had a significant negative effect, anxious-depressed symptoms (b =
.03 t[91] = 2.42, p <.05) had a significant positive effect, and sex (b = .75 t[91] = 4.39,
p <.001) was significant such that to being male was associated with waist circumference.
Finally, the third iteration of this model predicting BMI was statistically significant,
predicting 17.2% of the variance (R2 =.17, F [4, 90] = 4.68, p <.01). However, the
addition of anxious-depressed symptoms did not uniquely contribute to the significance.
Further analyses examining the possibility of interactions effects of between age, sex, and
SES with anxious-depressed symptoms on HDL, and waist circumference did not yield
significant findings.
Additionally, to investigate the possibility that metabolic problems may predict
anxious-depressed symptom, additional hierarchical multiple regression analyses were
conducted with anxious-depressed symptoms as the dependent variable. In step one, age,
sex, and SES were entered. In step two, HDL was entered. In step three, waist
circumference was added followed by BMI in step four. No significant effects were
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found, indicating that, in adults, anxious-depressed symptoms are more predictive of
metabolic problems than vice versa. The analysis was repeated with withdrawn-depressed
symptoms as the dependent variable, and there were also no significant findings.

Children
Sex, age, and socioeconomic status were used in step one of a hierarchical
multiple regression analysis to predict overall metabolic risk in children and adolescents.
In step two, anxious-depressed symptoms were added. The overall model was significant,
and predicted 26.3% of the variability in metabolic risk (R2 = .26, F [4, 95] = 8.46,
p <.001). However, the addition of anxious-depressed symptoms was not significant.
Next, we performed additional hierarchical multiple regressions predicting each
of the metabolic risk factors that were significantly correlated with anxious-depressed
and withdrawn symptoms. First, using withdrawn symptoms as the dependent variable,
age, SES, and sex were entered at step one of the regression. At step two, triglycerides
were added, followed by waist circumference at step three, and BMI at step four. The
overall model predicted 21% of the variance in withdrawn-depressed symptoms (R2 =.21,
F [6, 64] = 2.84, p < .05). Though the overall model was significant, none of the
individual predictors had significant independent effects on withdrawn-depressed
symptoms, suggesting a possible interaction effect. The analysis was repeated, predicting
anxious-depressed symptoms, and was not significant.
To examine possible interactive effects on withdrawn-depressed symptoms, we
computed cross product terms of “age x triglycerides”, and added it as a fifth step to the
model. The addition of the interaction term significantly improved the overall model,
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which now predicted 25% of the variance in withdrawn-depressed symptoms (R2= .25, F
[7, 63] = 3.05, p <.01). The interaction of age x triglycerides uniquely predicted 4.3% of
the variance, which was a marginally significant increase (ΔR2 =.04, ΔF [1, 63] = 3.59, p
= .063). To further explore this interaction, we used PROCESS to conduct follow-up
simple slope analyses at values of +/-1 standard deviation for age and triglycerides. For
younger children (-1 standard deviation), there was no significant effect of triglycerides
on withdrawn-depressed symptoms. However, for older children (+1 standard deviation),
there was a significant positive effect of triglycerides on withdrawn symptoms (b = .47,
t[63] = 2.47, p < .05; see Figure 1). Additionally, the Johnson-Neyman technique was
used to identify regions of significance, indicating a statistically significant effect of
triglycerides on withdrawn scores for children over the age of 12.68 years.
There were no significant interactions of between other variables in the model.
Finally, meeting full criteria for metabolic syndrome did not significantly predict
anxious-depressed or withdrawn symptoms in children

Discussion
The purpose of this study was to evaluate if there was a connection between
metabolic syndrome and anxiety and depression. The findings of the study partially
support the hypothesis, as anxiety was related to metabolic syndrome components in
adults and depression was related to metabolic syndrome components in children.
Although in the full sample, 1.4% of the overall metabolic risk was uniquely predicted by
anxious-depressed symptoms, further analyses indicated that the relations of anxiousdepressed symptoms and metabolic risk in adults drove this effect. Anxious-depressed
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symptoms predicted of 4.8% of the variance in overall metabolic risk in adults, and had
an effect such that higher levels of anxious-depressed symptoms were associated with
greater metabolic risk. Additionally, being older, male and of lower SES background
were risk factors for higher overall metabolic risk, lower levels of good cholesterol and a
large waist circumference. This finding is consistent with previous research insofar as
low SES and age have been previously identified as risk factors for metabolic syndrome
(Hildrum, Mykletun, Hole, Midthjell, & Dahl, 2007; Matthews, Raikkonen, Gallo, &
Kuller, 2008). However, inconsistent with the literature, most research has found that
women tend to have a greater risk of metabolic syndrome than men (Beigh & Jain, 2012;
Tonstad, Sandvik, Larsen, & Thelle, 2007). These inconsistencies may be due to the large
proportion of female adults in this sample of which may have reduced this studies ability
to detect effects of anxiety or depression on metabolic risk for males. Additionally, most
participants in this study resided in Vermont, a state that is healthier than other areas in
the United States (United Health Foundation America’s Health Rankings, 2016).
In adults, only anxious-depressed symptoms predicted metabolic problems,
specifically waist circumference and high-density lipoproteins. This finding is contrary to
the hypotheses that depression, but not anxiety would be related to all the components of
metabolic syndrome. This finding provides further evidence that anxiety is related to
metabolic problems, and supports the assertion that more research should be done
investigating anxiety and metabolic outcomes.
Inferences from the data imply anxiety may have a negative metabolic effect,
whereas depression may not. This may be explained by the fact that anxiety is a
psychological reaction to stress, even if the stressor is no longer present (Faravelli &
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Pallanti, 1989; Finlay-Jones & Brown, 1981; Schneiderman, Ironson, & Siegel, 2005).
Additionally, people with high levels of stress may have altered eating habits, choosing to
eat higher-calorie foods and increase overall consumption (Zellner et al., 2006). High
levels of stress are related to emotional eating, weight gain around the abdomen, and
increased blood pressure, all factors that contribute directly or indirectly to metabolic
syndrome (A. Chao et al., 2016). Behavioral changes, such as increased physical activity,
improved eating habits, and stress reduction techniques, such as meditation or
mindfulness may serve to both alleviate anxiety and reduce its negative metabolic
consequence (Daubenmier et al., 2011; Salmon, 2001).
In particular, large waist circumference and low HDL levels were the metabolic
risk factors predicted by anxious-depressed symptoms. Increased adipose tissue around
the abdomen contributes to lower levels of HDL (Nguyen-Duy, Nichaman, Church, Blair,
& Ross, 2003). Increased visceral adipose tissue has been shown to be a consequence of a
stress-induced cortisol response (Moyer et al., 1994). Negative metabolic outcomes may
be caused by an increase in the stress hormone cortisol due to chronic stress in
individuals with anxiety (A. M. Chao, Jastreboff, White, Grilo, & Sinha, 2017). A
proposed mechanism is that increased interleukins (cytokines) stimulate the release of
cortisol (Urwyler, Schuetz, Ebrahimi, Donath, & Christ-Crain, 2017). In a recent study,
interleukin antagonism in obese participants was found to lead to a decrease in cortisol,
systolic blood pressure, and heart rate (Urwyler et al., 2017). Anxiety, through stress and
cortisol release, may be related to negative metabolic outcomes. This relates anxiety to
metabolic syndrome.
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Unlike in adults, anxious-depressed symptoms did not predict metabolic outcomes
in children. However, the interaction between age and triglycerides did have an effect on
withdrawn-depressed symptoms, such that for children over the age of 12.68 years of age,
high levels of triglycerides were associated with more severe withdrawn-depressed
symptoms, whereas for children under the age 12.68, triglycerides had no effect. This is
in contrast with the hypothesis that the relations between anxiety, depression and
metabolic problems would be consistent across age. It is possible that triglyceride accrual
around the age of puberty may increase the risk of depressive symptoms, possibly related
to self-esteem and body dissatisfaction in adolescents, especially as steady weight gain
and increased body fat is associated with the onset of puberty (Lehrer, 2015; Ozmen et
al., 2007). This is further supported by a substantial body of research that has suggests
that obesity, which is associated with high triglyceride levels, may contribute to the early
onset of puberty (Ahmed, Ong, & Dunger, 2009). The early onset of puberty is also a risk
factor for depression (Birmaher et al., 1996; Wang, Lin, Leung, & Schooling, 2016;
Weissman, Warner, Wickramaratne, Moreau, & Olfson, 1997). It is possible that high
triglycerides may lead to weight gain, premature puberty, and depressive symptoms
during adolescence.
It is noteworthy, that in adults, internalizing psychiatric symptoms (e.g. anxiousdepressed) were found to uniquely contribute to metabolic risk, whereas in children, the
inverse relationship was observed. That is, in children, metabolic risk (specifically
triglycerides) uniquely predicted internalizing symptoms (i.e. withdrawn-depressed). This
may reflect an age-specific effect or separate mechanistic pathways. It is possible that
similarly to schizophrenia and bipolar disorder, inflammatory processes may underlie
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both the psychiatric and physiological symptoms in some individuals with anxiety and
depression. However, isolating those mechanisms was beyond the scope of the present
study. This study demonstrated a connection between symptoms of anxiety and
depression and metabolic problems, supporting the necessity for further research into the
cellular mechanisms of the disorders.

Limitations & Future Directions
This study had several limitations. First, because the design of the study was
cross-sectional, we could not make temporal inferences regarding the directionality of the
relations between anxiety and depression symptoms and metabolic problems.
Additionally, lifestyle (e.g. exercise, diet), medication usage, and comorbidity were not
controlled for in this study. Because these factors may have been related to both
psychiatric and metabolic symptoms, it will be important to examine these effects in
future research.
A larger sample size and more even ratios of females to males would also make
the study more generalizable. Additionally, as the participants were part of a family
study, and thus shared genetics and environment, there may have been an inflated
likelihood of significant findings.
Future directions include adding diet, exercise, biological relatedness, and
medication use to the hierarchical regression model. This can help to elucidate the impact
each of these factors has on psychological wellbeing and metabolic syndrome
components. Future studies should investigate participants longitudinally, as this can help
to determine directionality. Lastly, it would be interesting to look at this data set in
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relation to emotional eating and the HPA (hypothalamic-pituitary-adrenal) axis. This is
the idea that stress causes an increased desire for calorie-dense food. When comfort food
is eaten, it may alter signals in the brain, lowering the response to stress (Yau & Potenza,
2013). The HPA axis could be examined in part by adding blood cortisol levels, delay
discounting data, and diet to the model, as well as making the study longitudinal.

METSYN, ANXIETY, & DEPRESSION

25

Acknowledgements
I would like to give a special thanks to Dr. Robert Althoff for his wonderful
support throughout the process of writing this honors thesis. I would also like to thank the
rest of my wonderful committee, Dr. Alicia Ebert, Dr. Donna Toufexis, and Dr. Bryan
Ballif. Additionally, I would like to thank Merelise Ametti for all of her expertise, as it
was invaluable! Lastly, thank you to my family, boyfriend, and friends for all of their
support and love.

METSYN, ANXIETY, & DEPRESSION

26
References

Achenbach, T. M., & Rescorla, L. A. (2001). Manual for the ASEBA School-Age Forms
& Profiles. Burlington, Vermont: University of Vermont Research Center for
Children, Youth, and Families.
Aguilar, M., Bhuket, T., Torres, S., Liu, B., & Wong, R. J. (2015). Prevalence of the
metabolic syndrome in the United States, 2003-2012. The Journal of the
American Medical Association, 313(19), 1973-1974. doi:
10.1001/jama.2015.4260
Ahmed, M. L., Ong, K. K., & Dunger, D. B. (2009). Childhood obesity and the timing of
puberty. Trends in Endocrinology and Metabolism, 20(5), 237-242. doi:
10.1016/j.tem.2009.02.004
Alberti, K. G., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A.,
. . . International Association for the Study of, O. (2009). Harmonizing the
metabolic syndrome: a joint interim statement of the International Diabetes
Federation Task Force on Epidemiology and Prevention; National Heart, Lung,
and Blood Institute; American Heart Association; World Heart Federation;
International Atherosclerosis Society; and International Association for the Study
of Obesity. Circulation, 120(16), 1640-1645. doi:
10.1161/CIRCULATIONAHA.109.192644
Alberti, K. G., Zimmet, P., Shaw, J., & Group, I. D. F. E. T. F. C. (2005). The metabolic
syndrome--a new worldwide definition. Lancet, 366(9491), 1059-1062. doi:
10.1016/S0140-6736(05)67402-8
Anderson, S. E., Cohen, P., Naumova, E. N., Jacques, P. F., & Must, A. (2007).
Adolescent obesity and risk for subsequent major depressive disorder and anxiety
disorder: prospective evidence. Psychosomatic Medicine, 69(8), 740-747. doi:
10.1097/PSY.0b013e31815580b4
Beigh, S. H., & Jain, S. (2012). Prevalence of metabolic syndrome and gender
differences. Bioinformation, 8(13), 613-616. doi: 10.6026/97320630008613
Birmaher, B., Ryan, N. D., Williamson, D. E., Brent, D. A., Kaufman, J., Dahl, R. E., . . .
Nelson, B. (1996). Childhood and adolescent depression: a review of the past 10
years. Part I. Journal of the American Academy of Child and Adolescent
Psychiatry, 35(11), 1427-1439. doi: 10.1097/00004583-199611000-00011
Bly, M. J., Taylor, S. F., Dalack, G., Pop-Busui, R., Burghardt, K. J., Evans, S. J., . . .
Ellingrod, V. L. (2014). Metabolic syndrome in bipolar disorder and
schizophrenia: dietary and lifestyle factors compared to the general population.
Bipolar Disorders, 16(3), 277-288. doi: 10.1111/bdi.12160

METSYN, ANXIETY, & DEPRESSION

27

Butnoriene, J., Bunevicius, A., Norkus, A., & Bunevicius, R. (2014). Depression but not
anxiety is associated with metabolic syndrome in primary care based community
sample. Psychoneuroendocrinology, 40, 269-276. doi:
10.1016/j.psyneuen.2013.11.002
Carroll, D., Phillips, A. C., Thomas, G. N., Gale, C. R., Deary, I., & Batty, G. D. (2009).
Generalized anxiety disorder is associated with metabolic syndrome in the
Vietnam experience study. Biol Psychiatry, 66(1), 91-93. doi:
10.1016/j.biopsych.2009.02.020
Castillo, R. I., Rojo, L. E., Henriquez-Henriquez, M., Silva, H., Maturana, A., Villar, M.
J., . . . Gaspar, P. A. (2016). From Molecules to the Clinic: Linking Schizophrenia
and Metabolic syndrome through Sphingolipids Metabolism. Frontiers in
Neuroscience, 10, 488. doi: 10.3389/fnins.2016.00488
Center for Behavioral Health Statistics and Quality. (2016). Key substance use and
mental health indicators in the United States: Results from the 2015 National
Survey on Drug Use and Health (HHS Publication No. SMA 16-4984, NSDUH
Series H-51). Retrieved from http://www.samhsa.gov/data/
Chao, A., Grey, M., Whittemore, R., Reuning-Scherer, J., Grilo, C. M., & Sinha, R.
(2016). Examining the mediating roles of binge eating and emotional eating in the
relationships between stress and metabolic abnormalities. Journal of Behavioral
Medicine, 39(2), 320-332. doi: 10.1007/s10865-015-9699-1
Chao, A. M., Jastreboff, A. M., White, M. A., Grilo, C. M., & Sinha, R. (2017). Stress,
cortisol, and other appetite-related hormones: Prospective prediction of 6-month
changes in food cravings and weight. Obesity, 25(4), 713-720. doi:
10.1002/oby.21790
Chapman, D. P., Perry, G. S., & Strine, T. W. (2005). The vital link between chronic
disease and depressive disorders. Prev Chronic Dis, 2(1), A14.
Daubenmier, J., Kristeller, J., Hecht, F. M., Maninger, N., Kuwata, M., Jhaveri, K., . . .
Epel, E. (2011). Mindfulness Intervention for Stress Eating to Reduce Cortisol
and Abdominal Fat among Overweight and Obese Women: An Exploratory
Randomized Controlled Study. Journal of Obesity, 2011, 651936. doi:
10.1155/2011/651936
Engstrom, G., Hedblad, B., Stavenow, L., Lind, P., Janzon, L., & Lindgarde, F. (2003).
Inflammation-sensitive plasma proteins are associated with future weight gain.
Diabetes, 52(8), 2097-2101.
Faravelli, C., & Pallanti, S. (1989). Recent life events and panic disorder. The American
Journal of Psychiatry, 146(5), 622-626. doi: 10.1176/ajp.146.5.622

METSYN, ANXIETY, & DEPRESSION

28

Finlay-Jones, R., & Brown, G. W. (1981). types of stressful life event and the onset of
anxiety and depressive disorders. Psychological Medicine, 11(4), 803-815.
Good vs. Bad Cholesterol. (2017, April 3). Retrieved from
http://www.heart.org/HEARTORG/Conditions/Cholesterol/AboutCholesterol/Go
od-vs-Bad-Cholesterol_UCM_305561_Article.jsp#.WPDPc7HznVo
Greenberg, P. E., Fournier, A. A., Sisitsky, T., Pike, C. T., & Kessler, R. C. (2015). The
economic burden of adults with major depressive disorder in the United States
(2005 and 2010). The Journal of Clinical Psychiatry, 76(2), 155-162. doi:
10.4088/JCP.14m09298
Greenberg, P. E., Sisitsky, T., Kessler, R. C., Finkelstein, S. N., Berndt, E. R., Davidson,
J. R., . . . Fyer, A. J. (1999). The economic burden of anxiety disorders in the
1990s. The Journal of Clinical Psychiatry, 60(7), 427-435.
Halberg, N., Wernstedt-Asterholm, I., & Scherer, P. E. (2008). The adipocyte as an
endocrine cell. Endocrinology and Metabolism Clinics of North America, 37(3),
753-768, x-xi. doi: 10.1016/j.ecl.2008.07.002
Herva, A., Rasanen, P., Miettunen, J., Timonen, M., Laksy, K., Veijola, J., . . . Joukamaa,
M. (2006). Co-occurrence of metabolic syndrome with depression and anxiety in
young adults: the Northern Finland 1966 Birth Cohort Study. Psychosom Med,
68(2), 213-216. doi: 10.1097/01.psy.0000203172.02305.ea
High Blood Glucose. (2017). Retrieved from http://www.diabetes.org/are-you-atrisk/lower-your-risk/highbg.html?loc=atrisk-slabnav
High Blood Glucose: What it Means and How to Treat It. (2017). Retrieved from
http://www.joslin.org/info/high_blood_glucose_what_it_means_and_how_to_trea
t_it.html
Hildrum, B., Mykletun, A., Hole, T., Midthjell, K., & Dahl, A. A. (2007). Age-specific
prevalence of the metabolic syndrome defined by the International Diabetes
Federation and the National Cholesterol Education Program: the Norwegian
HUNT 2 study. BMC Public Health, 7, 220. doi: 10.1186/1471-2458-7-220
Hildrum, B., Mykletun, A., Midthjell, K., Ismail, K., & Dahl, A. A. (2009). No
association of depression and anxiety with the metabolic syndrome: the
Norwegian HUNT study. Acta Psychiatr Scand, 120(1), 14-22. doi:
10.1111/j.1600-0447.2008.01315.x
How is metabolic syndrome Diagnosed? (2016, June 22). Retrieved from
https://www.nhlbi.nih.gov/health/health-topics/topics/ms

METSYN, ANXIETY, & DEPRESSION

29

IBM Corp. Released 2016. IBM SPSS Statistics for Macintosh, Version 24.0. Armonk,
NY: IBM Corp.
Janssen, I., Heymsfield, S. B., Allison, D. B., Kotler, D. P., & Ross, R. (2002). Body
mass index and waist circumference independently contribute to the prediction of
nonabdominal, abdominal subcutaneous, and visceral fat. The American Journal
of Clinical Nutrition, 75(4), 683-688.
Kaur, J. (2014). A comprehensive review on metabolic syndrome. Cardiology Research
and Practice, 2014, 943162. doi: 10.1155/2014/943162
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E.
(2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders
in the National Comorbidity Survey Replication. Archives of General Psychiatry,
62(6), 593-602. doi: 10.1001/archpsyc.62.6.593
Kessler, R. C., Chiu, W. T., Demler, O., Merikangas, K. R., & Walters, E. E. (2005).
Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the
National Comorbidity Survey Replication. Archives of General Psychiatry, 62(6),
617-627. doi: 10.1001/archpsyc.62.6.617
Lau, D. C., Dhillon, B., Yan, H., Szmitko, P. E., & Verma, S. (2005). Adipokines:
molecular links between obesity and atheroslcerosis. American Journal of
Physiology. Heart and Circulatory Physiology, 288(5), H2031-2041. doi:
10.1152/ajpheart.01058.2004
Leboyer, M., Soreca, I., Scott, J., Frye, M., Henry, C., Tamouza, R., & Kupfer, D. J.
(2012). Can bipolar disorder be viewed as a multi-system inflammatory disease?
Journal of Affective Disorders, 141(1), 1-10. doi: 10.1016/j.jad.2011.12.049
Matthews, K. A., Raikkonen, K., Gallo, L., & Kuller, L. H. (2008). Association between
socioeconomic status and metabolic syndrome in women: testing the reserve
capacity model. Health Psychology: Official Journal of the Division of Health
Psychology, American Psychological Association, 27(5), 576-583. doi:
10.1037/0278-6133.27.5.576
McIntyre, R. S., Danilewitz, M., Liauw, S. S., Kemp, D. E., Nguyen, H. T., Kahn, L. S., .
. . Taylor, V. H. (2010). Bipolar disorder and metabolic syndrome: an
international perspective. Journal of Affective Disorders, 126(3), 366-387. doi:
10.1016/j.jad.2010.04.012
Meyer, J., Koro, C. E., & L'Italien, G. J. (2005). The metabolic syndrome and
schizophrenia: a review. International Review of Psychiatry, 17(3), 173-180. doi:
10.1080/09540260500071798

METSYN, ANXIETY, & DEPRESSION

30

Moyer, A. E., Rodin, J., Grilo, C. M., Cummings, N., Larson, L. M., & Rebuffe-Scrive,
M. (1994). Stress-induced cortisol response and fat distribution in women.
Obesity Research, 2(3), 255-262.
Nguyen-Duy, T. B., Nichaman, M. Z., Church, T. S., Blair, S. N., & Ross, R. (2003).
Visceral fat and liver fat are independent predictors of metabolic risk factors in
men. American Journal of Physiology. Endocrinology and Metabolism, 284(6),
E1065-1071. doi: 10.1152/ajpendo.00442.2002
Ozmen, D., Ozmen, E., Ergin, D., Cetinkaya, A. C., Sen, N., Dundar, P. E., & Taskin, E.
O. (2007). The association of self-esteem, depression and body satisfaction with
obesity among Turkish adolescents. BMC Public Health, 7, 80. doi:
10.1186/1471-2458-7-80
Rabasa, C., & Dickson, S. L. (2016). Impact of stress on metabolism and energy balance.
Current Opinion in Behavioral Sciences, 9, 71-77.
doi:http://dx.doi.org.ezproxy.uvm.edu/10.1016/j.cobeha.2016.01.011
Reece, J. B., Wasserman, S., Campbell, N. A., & Yunagisawa, M. (2011). Chapter 42
Circulation and Gas Exchange. In Campbell Biology Global Edition (9th ed., pp.
952-961). San Francisco, CA: Pearson Benjamin Cummings.
Rodriguez-Hernandez, H., Simental-Mendia, L. E., Rodriguez-Ramirez, G., & ReyesRomero, M. A. (2013). Obesity and inflammation: epidemiology, risk factors, and
markers of inflammation. International Journal of Endocrinology, 2013, 678159.
doi: 10.1155/2013/678159
Salmon, P. (2001). Effects of physical exercise on anxiety, depression, and sensitivity to
stress: a unifying theory. Clinical Psychology Review, 21(1), 33-61.
Schmidt, F. M., Weschenfelder, J., Sander, C., Minkwitz, J., Thormann, J., Chittka, T., . .
. Himmerich, H. (2015). Inflammatory cytokines in general and central obesity
and modulating effects of physical activity. PLoS One, 10(3), e0121971. doi:
10.1371/journal.pone.0121971
Schneiderman, N., Ironson, G., & Siegel, S. D. (2005). Stress and health: psychological,
behavioral, and biological determinants. Annual Review of Clinical Psychology, 1,
607-628. doi: 10.1146/annurev.clinpsy.1.102803.144141
Skilton, M. R., Moulin, P., Terra, J. L., & Bonnet, F. (2007). Associations between
anxiety, depression, and the metabolic syndrome. Biological Psychiatry, 62(11),
1251-1257. doi: 10.1016/j.biopsych.2007.01.012
The Power of Prevention Chronic disease . . . the public health challenge of the 21st
century (Rep.). (2009). Retrieved https://www.cdc.gov/chronicdisease/pdf/2009power-of-prevention.pdf

METSYN, ANXIETY, & DEPRESSION

31

Thorand, B., Lowel, H., Schneider, A., Kolb, H., Meisinger, C., Frohlich, M., & Koenig,
W. (2003). C-reactive protein as a predictor for incident diabetes mellitus among
middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998.
Archives of Internal Medicine, 163(1), 93-99.
Tonstad, S., Sandvik, E., Larsen, P. G., & Thelle, D. (2007). Gender differences in the
prevalence and determinants of the metabolic syndrome in screened subjects at
risk for coronary heart disease. Metabolic syndrome and Related Disorders, 5(2),
174-182. doi: 10.1089/met.2006.0037
Trayhurn, P., & Wood, I. S. (2004). Adipokines: inflammation and the pleiotropic role of
white adipose tissue. The British Journal of Nutrition, 92(3), 347-355.
Triglycerides: Why do they matter? (2015, August 15). Retrieved from
http://www.mayoclinic.org/diseases-conditions/high-blood-cholesterol/indepth/triglycerides/art-20048186
Urwyler, S. A., Schuetz, P., Ebrahimi, F., Donath, M. Y., & Christ-Crain, M. (2017).
Interleukin-1 antagonism decreases cortisol levels in obese individuals. The
Journal of Clinical Endocrinology and Metabolism. doi: 10.1210/jc.2016-3931
Wang, H., Lin, S. L., Leung, G. M., & Schooling, C. M. (2016). Age at Onset of Puberty
and Adolescent Depression: "Children of 1997" Birth Cohort. Pediatrics, 137(6).
doi: 10.1542/peds.2015-3231
Weiss, R., Dziura, J., Burgert, T. S., Tamborlane, W. V., Taksali, S. E., Yeckel, C. W., . .
. Caprio, S. (2004). Obesity and the metabolic syndrome in children and
adolescents. The New England Journal of Medicine, 350(23), 2362-2374. doi:
10.1056/NEJMoa031049
Weissman, M. M., Warner, V., Wickramaratne, P., Moreau, D., & Olfson, M. (1997).
Offspring of depressed parents. 10 Years later. Archives of General Psychiatry,
54(10), 932-940.
World Health Organization, The top 10 causes of death. (2017, January). Retrieved
March 27, 2017, from http://www.who.int/mediacentre/factsheets/fs310/en/
Yau, Y. H., & Potenza, M. N. (2013). Stress and eating behaviors. Minerva Endocrinol,
38(3), 255-267.
Zellner, D. A., Loaiza, S., Gonzalez, Z., Pita, J., Morales, J., Pecora, D., & Wolf, A.
(2006). Food selection changes under stress. Physiology & Behavior, 87(4), 789793. doi: 10.1016/j.physbeh.2006.01.014
2016 Senior Report. (2016). Retrieved from http://www.americashealthrankings.org/
learn/reports/2016-senior-report/findings-top-bottom-states

METSYN, ANXIETY, & DEPRESSION

32
Appendix

Sample
N=257
Mean
Standard
Deviation
Minimum
Maximum
N
Missing (N)
% Male
% Female

Sex
.50
.50

SES
65.98
22.97

Children
N=140
Age Sex
26.00 .66
16.76 .48

0
1
257
0
50.2
49.8

0
90
251
6
-

7
60
257
0
-

Table 1. Descriptive Statistics

0
1
140
0
65.7
34.3

Adults
N=117
SES Age Sex
SES Age
65.43 11.36 .31
66.65 43.51
23.99 2.81 .46
21.73 6.51
0
90
139
1
-

7
17
140
0
-

0
1
117
0
30.8
69.2

0
90
112
5
-

28
60
117
0
-
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Pearson’s Correlation
(N= 89-249)
Measure

All Subjects Average Z Score
Adults Average Z Score
Children Average Z Score
Children & Adults Average Z
Score
BMI
BMI Children Average Z Score
BMI Adults Average Z Score
Waist Circumference All
Subjects Average Z Score
Waist Circumference Adults
Average Z Score
Waist Circumference Children
Average Z Score
HDL Adult Average Z Score
Triglycerides Children Average
Z Score
Metabolic syndrome Diagnosis
**p<.01, *p <.05 (2-tailed)
Table 2. Pearson’s Correlations
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Anxious
Depressed Raw
Score
.235**
.245*
.132
.169*

Withdrawn
Raw Score

.296**
.195
.228*
.286**

.140*
.358**
.134
.146*

.257*

.150

.132

.292**

.215
.198

.043
.286*

.077

.039

.119
.108
.263**
.191*
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4

Withdrawn Raw Score

3.5
3
2.5
2

Younger Children

1.5

Older Children

1
0.5
0
Low Triglycerides
High Triglycerides
Triglycerides Z Score

Figure 1. The moderating effect of age on triglycerides predicting depressive behavior

